Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Melanoma: KOL Insight: Update Bulletin [August 2017]

Product Code:
596200723
Publication Date:
August 2017
Format:
PDF
Price:
€975

This edition presents key opinion leader (KOL) views on recent developments in the malignant melanoma (MM) market. Topics covered include: Array BioPharma submission of two New Drug Applications (NDAs) to the US Food and Drug Administration (FDA) for the combination of binimetinib and encorafenib for BRAF-mutant advanced, unresectable or metastatic melanoma; Merck & Co.’s updated longer-term overall survival (OS) data from Phase III KEYNOTE-006 study for pembrolizumab (Keytruda), in patients with unresectable or metastatic melanoma and Amgen’s new data from the Phase II '264 study for talimogene laherparepvec (Imlygic) in combination with ipilimumab (Yervoy).

  • How do KOLs view the arrival of Array BioPharma’s binimetinib/encorafenib combination to the melanoma treatment landscape?
  • How does Array’s binimetinib/encorafenib compare to Novartis’ trametinib/dabrafenib combination?
  • Could encorafenib/binimetinib, as the new entrant overhaul Novartis’ lead in this segment?
  • How do KOLs view the KEYNOTE-006 study data for Keytruda?
  • What impact will new data for Keytruda have on Bristol‑Myers Squibb’s Yervoy?
  • How do KOLs view the potential of Amgen’s Imlygic/Yervoy combination therapy?
  • Is Imlygic /Yervoy combination likely to give way to Imlygic/Keytruda? What do KOLs think?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved